Imaging test for Trop2 in triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new imaging agent (99mTc-MY6349) to see if it can detect Trop2, a protein found on some breast cancer cells. It may help doctors better see and understand triple-negative breast cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 80 years old.
- You have been diagnosed with or are suspected to have triple-negative breast cancer that has come back or spread to other parts of the body.
- You are either surgically sterile, past menopause for more than one year, or willing to use effective birth control during the study.
- You do not have severe health problems like heart, liver, kidney, or blood disorders.
- You are not pregnant or breastfeeding.
- You have not been in another research study with radiation in the past year that would exceed a safe total dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This trial uses a special PET scan to see if a type of drug called Trop2-ADC is working in people with advanced breast cancer. The scan may help doctors decide if the treatment is right for you.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
This study tests a new imaging agent that targets a protein called ACE, which may be found in triple-negative breast cancer. The imaging will help doctors see the cancer more clearly and could aid in planning your treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.